PMID- 23189160
OWN - NLM
STAT- MEDLINE
DCOM- 20130516
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 7
IP  - 11
DP  - 2012
TI  - Extracorporeal Shock Wave Treatment (ESWT) improves in vitro functional 
      activities of ruptured human tendon-derived tenocytes.
PG  - e49759
LID - 10.1371/journal.pone.0049759 [doi]
LID - e49759
AB  - In vitro models of human tenocytes derived from healthy as well as from ruptured 
      tendons were established, characterized and used at very early passage (P1) to 
      evaluate the effects of Extracorporeal Shock Wave Treatment (ESWT). The molecular 
      analysis of traditional tenocytic markers, including Scleraxis (Scx), Tenomodulin 
      (Tnm), Tenascin-C (Tn-C) and Type I and III Collagens (Col I and Col III), 
      permitted us to detect in our samples the simultaneous expression of all these 
      genes and allowed us to compare their levels of expression in relationship to the 
      source of the cells and treatments. In untreated conditions, higher molecular 
      levels of Scx and Col I in tenocytes from pathological compared to healthy 
      samples have been detected, suggesting--in the cells from injured tendon--the 
      natural trigger of an early differentiation and repairing program, which depends 
      by Scx and requires an increase in collagen expression. When ESWT (at the dose of 
      0.14 mJ/mm(2)) was applied to cultured tenocytes explanted from injured source, 
      Scx and Col I were significantly diminished compared to healthy counterpart, 
      indicating that such natural trigger maybe delayed by the treatment, in order to 
      promote cellular repair. Herein, we show for the first time that ESWT enhances in 
      vitro functional activities of ruptured tendon-derived tenocytes, such as 
      proliferation and migration, which could probably contributes to tendon healing 
      in vivo.
FAU - Leone, Laura
AU  - Leone L
AD  - Department of Clinical and Molecular Medicine, Istituto Pasteur-Fondazione Cenci 
      Bolognetti, Sapienza University of Rome, Rome, Italy.
FAU - Vetrano, Mario
AU  - Vetrano M
FAU - Ranieri, Danilo
AU  - Ranieri D
FAU - Raffa, Salvatore
AU  - Raffa S
FAU - Vulpiani, Maria Chiara
AU  - Vulpiani MC
FAU - Ferretti, Andrea
AU  - Ferretti A
FAU - Torrisi, Maria Rosaria
AU  - Torrisi MR
FAU - Visco, Vincenzo
AU  - Visco V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121126
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (SCX protein, human)
RN  - 0 (Tenascin)
RN  - 9007-34-5 (Collagen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Basic Helix-Loop-Helix Transcription Factors/metabolism
MH  - Cells, Cultured
MH  - Collagen/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Primary Cell Culture
MH  - Tenascin/metabolism
MH  - Tendon Injuries/*metabolism/therapy
MH  - Tendons/*cytology/*metabolism
MH  - Young Adult
PMC - PMC3506633
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2012/11/29 06:00
MHDA- 2013/05/17 06:00
PMCR- 2012/11/26
CRDT- 2012/11/29 06:00
PHST- 2012/08/07 00:00 [received]
PHST- 2012/10/11 00:00 [accepted]
PHST- 2012/11/29 06:00 [entrez]
PHST- 2012/11/29 06:00 [pubmed]
PHST- 2013/05/17 06:00 [medline]
PHST- 2012/11/26 00:00 [pmc-release]
AID - PONE-D-12-23951 [pii]
AID - 10.1371/journal.pone.0049759 [doi]
PST - ppublish
SO  - PLoS One. 2012;7(11):e49759. doi: 10.1371/journal.pone.0049759. Epub 2012 Nov 26.